In the pursuit of more effective breast cancer therapies, the investigation of interactions between novel compounds and established chemotherapeutics has become increasingly important. This study investigates the combinatory effects of alpha-mangostin (α-MG) and nab-paclitaxel on MCF-7 and MDA-MB-231 cell lines, utilizing the xCELLigence RTCA system for continuous real-time cellular analysis, BrdU incorporation assays for proliferation assessment, and the quantification of mitotic activity and caspase-3/7 levels to elucidate apoptotic mechanisms. Our findings demonstrate that both α-MG and nab-paclitaxel independently induce significant inhibition of cellular proliferation and modulate cell cycle dynamics over a 24 to 72-hour period. Notably, when combined, these agents exhibit a pronounced enhancement of cell cycle inhibition and apoptosis, surpassing the effects observed with monotherapy. This potentiation effect suggests that α-MG augments the therapeutic efficacy of nab-paclitaxel, potentially allowing for reduced dosages in clinical applications. The study underscores the potential of α-MG as an adjuvant in breast cancer treatment, offering a promising strategy to optimize therapeutic regimens, minimize adverse effects, and improve patient outcomes in clinical oncology.
Read full abstract